TG Therapeutics Investigational Trial Site

Dallas, Texas 75390

1 studies enrolling now · 5 studies all time

What they study most

Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Small Lymphocytic Lymphoma

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis — Running, not enrolling
• Ublituximab + Ibrutinib in Select B-cell Malignancies — Completed
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma — Stopped early
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) — Completed